CDE ID | CDE Description | * 1063 | Site Participant ID (Go To: 422) |
* 422 | EDRN Site ID (Go To: 421) |
* 421 | EDRN Participant ID (Go To: 1319) |
* 1319 | Date participant signed consent form (MM/DD/YYYY): (Go To: 1429) |
* 1429 | Year of birth (In what year were you born?) (Go To: 1322) |
1322 | Hispanic or Latino (Are you Hispanic or Latino?) (Go To: 1315) |
| Permissible Values (value): | No (0) |
|
| |
| |
1315 | Race (What is your race? Check all that apply.) (Go To: 1837) |
| Permissible Values (value): | White (1) |
|
| | Black or African-American (2) |
|
| | American Indian or Alaska Native (3) |
|
| |
| | Native Hawaiian or other Pacific Islander (7) |
|
| |
| |
1837 | Date of cancer diagnosis (MM/DD/YYYY): (Go To: 2646) |
* 2646 | Neoadjuvant therapy(s) administered: (Go To: 774) |
| Permissible Values (value): | Chemotherapy (1) |
|
| |
| |
| |
| |
| |
| |
* 774 | Date of surgery (MM/DD/YYYY): (Go To: 2605) |
2605 | Surgery type: (Go To: 2607) |
| Permissible Values (value): | Laprascopic/Robotic (1) |
|
| |
| |
2607 | Nerve-sparing surgery? (Go To: 1589) |
| Permissible Values (value): | No (0) |
|
| |
| |
* 1589 | Primary Gleason grade: (Go To: 1590) |
1590 | Secondary Gleason grade: (Go To: 1696) |
1696 | Tertiary Gleason Pattern: (Go To: 1697) |
1697 | Overall Gleason Score: (Go To: 2628) |
* 2628 | Seminal vesicle invasion? (Go To: 2629) |
| Permissible Values (value): | No (0) |
|
| |
| |
2629 | Seminal vesicle invasion site: (Go To: 2721) |
| Permissible Values (value): | Right (1) |
|
| |
| |
| |
| |
* 2721 | Extracapsular invasion? (Go To: 2720) |
| Permissible Values (value): | No (0) |
|
| |
| |
2720 | Extracapsular invasion site: (Go To: 2618) |
| Permissible Values (value): | Right (1) |
|
| |
| |
| |
| |
* 2618 | Margin status (presence of cancer at margin): (Go To: 2723) |
| Permissible Values (value): | Positive (1) |
|
| |
| | Uncertain (borderline case) (3) |
|
| |
* 2723 | Lymph node status: (Go To: 2614) |
| Permissible Values (value): | Positive (1) |
|
| |
| | Uncertain (borderline case) (3) |
|
| |
2614 | Estimated tumor volume (cc): (Go To: 2210) |
2210 | Percent of cancer in tissue: (Go To: 2615) |
2615 | Tumor volume determination method: (Go To: 2608) |
| Permissible Values (value): | Nickel method (1) |
|
| | Volume calculation by mass (2) |
|
| |
| | Greatest linear dimension (4) |
|
| |
| |
2722 | Prostate volume (cc): (Go To: 2610) |
2608 | Prostate weight (g): (Go To: 2722) |
2610 | Prostate T-Stage, Pathologic: (Go To: 2750) |
| Permissible Values (value): | pT0 (2) |
|
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
2750 | AJCC Manual edition: (Go To: 1878) |
| Permissible Values (value): | Edition 1 went into effect 1978 (1) |
|
| | Edition 2 went into effect 1984 (2) |
|
| | Edition 3 went into effect 1993 (3) |
|
| | Edition 4 went into effect 1997 (4) |
|
| | Edition 5 went into effect 1998 (5) |
|
| | Edition 6 went into effect 2003 (6) |
|
| | Edition 7 went into effect 2010 (7) |
|
| |
* 1878 | Date of last contact (MM/DD/YYYY): (Go To: 2719) |
* 2719 | Adjuvant therapy administered: (Go To: 2638) |
| Permissible Values (value): | Chemotherapy (1) |
|
| |
| |
| |
| |
| |
| |
2638 | Recurrent cancer? (Go To: 1221) |
| Permissible Values (value): | No (0) |
|
| |
| |
1221 | Recurrence date (MM/YYYY): (Go To: 2724) |
* 2724 | Date of metastatic recurrence (MM/YYYY): (Go To: 2725) |
* 2725 | Salvage therapy administered: (Go To: 1869) |
| Permissible Values (value): | Chemotherapy (1) |
|
| |
| |
| |
| |
| |
| |
* 1869 | Treatment start date (MM/DD/YYYY): (Go To: 1272) |
1272 | Living status: (Go To: 1336) |
| Permissible Values (value): | Alive with disease (1) |
|
| | Alive with no evidence of disease (NED) (2) |
|
| |
| |
1336 | Date of death (MM/DD/YYYY): (Go To: 2726) |
2726 | Death related to study outcome? (Go To: 3993) |
| Permissible Values (value): | No (0) |
|
| |
| |
* 3993 | DMCC Eligibility (TMA study group) (Go To: 1097) |
| Permissible Values (value): | Non-recurrent (1) |
|
| |
| |
| |
| |
1097 | Comments (do not include any participant identifiers) (Go To: 2749) |
2749 | Coordinating center data comments: (Go To: End of Form) |